


# Phase-Transfer-Catalyzed Asymmetric $S_NAr$ Reaction of $\alpha$ -Amino Acid Derivatives with Arene Chromium Complexes\*\*

Seiji Shirakawa, Kenichiro Yamamoto, and Keiji Maruoka\*

**Abstract:** Although phase-transfer-catalyzed asymmetric  $S_NAr$  reactions provide unique contribution to the catalytic asymmetric  $\alpha$ -arylations of carbonyl compounds to produce biologically active  $\alpha$ -aryl carbonyl compounds, the electrophiles were limited to arenes bearing strong electron-withdrawing groups, such as a nitro group. To overcome this limitation, we examined the asymmetric  $S_NAr$  reactions of  $\alpha$ -amino acid derivatives with arene chromium complexes derived from fluoroarenes, including those containing electron-donating substituents. The arylation was efficiently promoted by binaphthyl-modified chiral phase-transfer catalysts to give the corresponding  $\alpha,\alpha$ -disubstituted  $\alpha$ -amino acids containing various aromatic substituents with high enantioselectivities.

Catalytic asymmetric  $\alpha$ -arylation of carbonyl compounds has been extensively studied over the last decade to prepare biologically interesting  $\alpha$ -aryl carbonyl compounds.<sup>[1,2]</sup> Several catalytic asymmetric methods for  $\alpha$ -arylation have been developed using chiral metal complexes.<sup>[3]</sup> As another method for asymmetric  $\alpha$ -arylation, the phase-transfer-catalyzed nucleophilic aromatic substitution ( $S_NAr$ ) reaction provides an efficient means to realize enantioselective  $\alpha$ -arylations (Scheme 1).<sup>[4,5]</sup> Jørgensen's and our groups have reported highly enantioselective phase-transfer-catalyzed  $S_NAr$  reactions of carbonyl compounds with nitro group-bearing fluoroarenes as electrophiles (Scheme 1a).<sup>[6]</sup> The drawback of this method is the limited scope of fluoroarenes that can be used, as only electron-deficient arenes are effective substrates. The  $S_NAr$  reactions using fluoroarenes with electron-donating groups (EDG), did not work under the phase-transfer conditions (Scheme 1b). As a solution to this problem, we are interested in  $S_NAr$  reaction of the chromium complexes of fluoroarenes, which activate the arenes through  $\eta^6$ -coordination to  $Cr(CO)_3$ .<sup>[7,8]</sup> Here we report a valuable example of a phase-transfer-catalyzed asymmetric  $S_NAr$  reaction of  $\alpha$ -amino acid derivatives with arene chromium



**Scheme 1.** Phase-transfer-catalyzed asymmetric  $S_NAr$  reactions. PTC = phase-transfer catalyst.

complexes, which produces enantioenriched  $\alpha,\alpha$ -disubstituted  $\alpha$ -amino acids<sup>[9]</sup> including those containing an electron-rich aromatic substituents (Scheme 1c).

We first examined the asymmetric  $S_NAr$  reaction of alanine derivative **1a** with chromium complex **2a** derived from fluorobenzene, promoted by biaryl-modified chiral quaternary ammonium salts **4–6** as promising chiral phase-transfer catalysts (Table 1).<sup>[5]</sup> Attempted reaction of **1a** and fluorobenzene derivative **2a** with solid KOH in toluene under the influence of chiral phase-transfer catalyst (*R,R*)-**4**<sup>[10]</sup> at 0 °C for 24 h, followed by treatment with aqueous HCl for hydrolysis of the imine moiety and removal of chromium, afforded the corresponding  $\alpha,\alpha$ -disubstituted  $\alpha$ -amino ester **3a** with moderate yield and enantioselectivity (77% *ee*, entry 1). The use of simplified catalyst (*R*)-**5**,<sup>[11]</sup> which is one of the most effective catalysts for asymmetric alkylation reactions of **1a**,<sup>[11,12]</sup> improved the enantioselectivity to give product **3a** in moderate yield with high enantioselectivity (97% *ee*, entry 2). The use of biphenyl-modified catalyst (*R*)-**6**<sup>[13]</sup> caused the decrease of enantioselectivity for the  $S_NAr$  reaction (39% *ee*, entry 3). Changing the base to CsOH improved the yield (entry 4), and the highest yield and enantioselectivity was attained by the use of saturated aqueous CsOH<sup>[14]</sup> as base with catalyst (*R*)-**5** (entry 5).<sup>[15]</sup> The absolute configuration of product **3a** was determined by comparison of the optical rotation of the *N*-acetylated derivative of **3a** with the literature value.<sup>[6c,16]</sup>

[\*] Prof. Dr. S. Shirakawa, K. Yamamoto, Prof. Dr. K. Maruoka  
Department of Chemistry, Graduate School of Science  
Kyoto University  
Sakyo, Kyoto 606-8502 (Japan)  
E-mail: maruoka@kuchem.kyoto-u.ac.jp

Prof. Dr. S. Shirakawa  
Graduate School of Fisheries Science and Environmental Studies  
Nagasaki University  
1-14, Bunkyo-machi, Nagasaki 852-8521 (Japan)

[\*\*] This work was supported by a Grant-in-Aid for Scientific Research from JSPS and MEXT (Japan).

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201409065>.

**Table 1:** Optimization of the reaction conditions.<sup>[a]</sup>

| Entry | Catalyst         | Base                  | Yield [%] <sup>[b]</sup> | ee [%] <sup>[c]</sup> |
|-------|------------------|-----------------------|--------------------------|-----------------------|
| 1     | ( <i>R,R</i> )-4 | KOH                   | 42                       | 77                    |
| 2     | ( <i>R</i> )-5   | KOH                   | 39                       | 97                    |
| 3     | ( <i>R</i> )-6   | KOH                   | 41                       | 39                    |
| 4     | ( <i>R</i> )-5   | CsOH·H <sub>2</sub> O | 70                       | 91                    |
| 5     | ( <i>R</i> )-5   | sat. aq. CsOH         | 70                       | 97                    |

[a] Reaction conditions: **1a** (0.30 mmol), **2a** (0.10 mmol), and base (1.5 mmol) in the presence of phase-transfer catalyst (10 mol %, 0.010 mmol) in toluene (2.0 mL) at 0 °C for 24 h. [b] Yields of isolated product **3a**, which were determined on the basis of the amount of **2a**. [c] Determined by HPLC analysis on a chiral stationary phase.

With the optimal reaction conditions identified, we next examined the substrate generality of the asymmetric S<sub>N</sub>Ar reaction of alanine derivative **1a** with arene chromium complexes **2** under the influence of chiral phase-transfer catalyst (*R*)-5 (Table 2). The S<sub>N</sub>Ar reactions with *p*-, *m*-, and *o*-fluorotoluene derivatives (**2b–2d**) proceeded efficiently, and gave the products (**3b–3d**) in good yields with high enantioselectivities (94–98 % ee, entries 2–4). Other electron-donating group (EDG)-substituted fluoroarene derivatives (**2e–2i**) could also be used in this reaction, thereby providing the products (**3e–3i**) with excellent enantioselectivities (98–99 % ee, entries 5–9).<sup>[17]</sup>

Other α-amino acid derivatives **1** could be employed in the S<sub>N</sub>Ar reaction with arene chromium complex **2a** (Table 3). Not only simple alkyl-substituted α-amino acid derivatives (**1a–1c**) but also phenylalanine (**1d**) and allylglycine (**1e**) derivatives were tolerated in the reaction to give the corresponding phenylation products **3j–3m** in high enantioselectivities (88–99 % ee, entries 1–5). Furthermore, heteroatom-containing α-amino acids, such as methionine (**1f**), serine (**1g**), and glutamic acid derivatives (**1h**), were also suitable for the reaction to give the corresponding products **3n–3p** in high enantioselectivities (90–96 % ee, entries 6–8).

**Table 2:** Asymmetric arylation of alanine derivative **1a**.<sup>[a]</sup>

| Entry | EDG ( <b>2</b> )                         | Yield [%] <sup>[b]</sup> | ee [%] <sup>[c]</sup> |
|-------|------------------------------------------|--------------------------|-----------------------|
| 1     | H ( <b>2a</b> )                          | 70 ( <b>3a</b> )         | 97                    |
| 2     | <i>p</i> -Me ( <b>2b</b> )               | 71 ( <b>3b</b> )         | 98                    |
| 3     | <i>m</i> -Me ( <b>2c</b> )               | 69 ( <b>3c</b> )         | 98                    |
| 4     | <i>o</i> -Me ( <b>2d</b> )               | 62 ( <b>3d</b> )         | 94                    |
| 5     | <i>p</i> -OMe ( <b>2e</b> )              | 70 ( <b>3e</b> )         | 98                    |
| 6     | <i>m</i> -OMe ( <b>2f</b> )              | 68 ( <b>3f</b> )         | 99                    |
| 7     | <i>p</i> -OEt ( <b>2g</b> )              | 61 ( <b>3g</b> )         | 98                    |
| 8     | <i>p</i> -SMe ( <b>2h</b> )              | 65 ( <b>3h</b> )         | 99                    |
| 9     | <i>p</i> -NMe <sub>2</sub> ( <b>2i</b> ) | 63 ( <b>3i</b> )         | 98                    |

[a] Reaction conditions: **1a** (0.30 mmol), **2** (0.10 mmol), and saturated aqueous CsOH (1.5 mmol) in the presence of (*R*)-5 (10 mol %, 0.010 mmol) in toluene (2.0 mL) at 0 °C for 24 h. [b] Yields of isolated products **3**, which were determined on the basis of the amount of **2**. [c] Determined by HPLC analysis on a chiral stationary phase.

**Table 3:** Asymmetric phenylation of α-amino acid derivatives **1**.<sup>[a]</sup>

| Entry | R ( <b>1</b> )                                                    | Yield [%] <sup>[b]</sup> | ee [%] <sup>[c]</sup> |
|-------|-------------------------------------------------------------------|--------------------------|-----------------------|
| 1     | Me ( <b>1a</b> )                                                  | 70 ( <b>3a</b> )         | 97                    |
| 2     | Et ( <b>1b</b> )                                                  | 78 ( <b>3j</b> )         | 99                    |
| 3     | <i>i</i> Bu ( <b>1c</b> )                                         | 60 ( <b>3k</b> )         | 88                    |
| 4     | CH <sub>2</sub> Ph ( <b>1d</b> )                                  | 68 ( <b>3l</b> )         | 95                    |
| 5     | CH <sub>2</sub> CH=CH <sub>2</sub> ( <b>1e</b> )                  | 74 ( <b>3m</b> )         | 96                    |
| 6     | CH <sub>2</sub> CH <sub>2</sub> SMe ( <b>1f</b> )                 | 76 ( <b>3n</b> )         | 90                    |
| 7     | CH <sub>2</sub> OEtBu ( <b>1g</b> )                               | 73 ( <b>3o</b> )         | 96                    |
| 8     | CH <sub>2</sub> CH <sub>2</sub> CO <sub>2</sub> tBu ( <b>1h</b> ) | 51 ( <b>3p</b> )         | 92                    |

[a] Reaction conditions: **1** (0.30 mmol), **2a** (0.10 mmol), and saturated aqueous CsOH (1.5 mmol) in the presence of (*R*)-5 (10 mol %, 0.010 mmol) in toluene (2.0 mL) at 0 °C for 24 h. [b] Yields of isolated products **3**, which were determined on the basis of amount of **2a**. [c] Determined by HPLC analysis on a chiral stationary phase.

In summary, we have successfully overcome a major limitation of phase-transfer-catalyzed asymmetric S<sub>N</sub>Ar reactions by the use of arene chromium complexes. The S<sub>N</sub>Ar reaction of α-amino acid derivatives with chromium complexes derived from electron-rich fluoroarenes, was efficiently promoted by binaphthyl-modified chiral phase-transfer catalysts to give the corresponding α,α-disubstituted α-amino acids containing various aromatic substituents, in a highly enantioselective manner. This report offers a new option for

catalytic asymmetric  $\alpha$ -arylation to produce biologically active  $\alpha$ -aryl carbonyl compounds.

Received: September 13, 2014

Published online: November 24, 2014

**Keywords:** amino acids · arylation · asymmetric synthesis · organocatalysis · phase-transfer catalysis

- [1] For reviews on  $\alpha$ -arylation, see: a) A. C. B. Burtoloso, *Synlett* **2009**, 320; b) C. C. C. Johansson, T. J. Colacot, *Angew. Chem. Int. Ed.* **2010**, 49, 676; *Angew. Chem.* **2010**, 122, 686; c) F. Bellina, R. Rossi, *Chem. Rev.* **2010**, 110, 1082; d) C. Mazet, *Synlett* **2012**, 1999.
- [2] For examples of biologically active  $\alpha$ -aryl carbonyl compounds, see: a) H. U. Stilz, W. Guba, B. Jablonka, M. Just, O. Klingler, W. König, V. Wehner, G. Zoller, *J. Med. Chem.* **2001**, 44, 1158; b) H. Venkatesan, M. C. Davis, Y. Altas, J. P. Snyder, D. C. Liotta, *J. Org. Chem.* **2001**, 66, 3653; c) T. Hatanaka, Y. Nabuchi, H. Ushio, *J. Pharm. Pharmacol.* **2002**, 54, 549; d) C. Zha, G. B. Brown, W. J. Brouillette, *J. Med. Chem.* **2004**, 47, 6519; e) A. Natarajan, Y. Guo, F. Harbinski, Y.-H. Fan, H. Chen, L. Luus, J. Diercks, H. Aktas, M. Chorev, J. A. Halperin, *J. Med. Chem.* **2004**, 47, 4979; f) D. A. Neel, M. L. Brown, P. A. Lander, T. A. Grese, J. M. Defauw, R. A. Doti, T. Fields, S. A. Kelley, S. Smith, K. M. Zimmerman, M. I. Steinberg, P. K. Jadhav, *Bioorg. Med. Chem. Lett.* **2005**, 15, 2553; g) K. H. Mortell, D. J. Anderson, J. J. Lynch III, S. L. Nelson, K. Sarris, H. McDonald, R. Sabet, S. Baker, P. Honore, C.-H. Lee, M. F. Jarvis, M. Gopalakrishnan, *Bioorg. Med. Chem. Lett.* **2006**, 16, 1138; h) Y.-J. Kwon, M.-J. Sohn, C.-J. Zheng, W.-G. Kim, *Org. Lett.* **2007**, 9, 2449; i) M. K. Uddin, S. G. Reignier, T. Coulter, C. Montalbetti, C. Grånäs, S. Butcher, C. Krog-Jensen, J. Felding, *Bioorg. Med. Chem. Lett.* **2007**, 17, 2854; j) M. K. Christensen, K. D. Erichsen, C. Trojel-Hansen, J. Tjørnelund, S. J. Nielsen, K. Frydenvang, T. N. Johansen, B. Nielsen, M. Sehested, P. B. Jensen, M. Ikaunieks, A. Zaichenko, E. Loza, I. Kalvinsh, F. Björklund, *J. Med. Chem.* **2010**, 53, 7140; k) F. Nique, S. Hebbe, C. Peixoto, D. Annot, J.-M. Lefrançois, E. Duval, L. Michoux, N. Triballeau, J.-M. Lemoullec, P. Mollat, M. Thauvin, T. Prangé, D. Minet, P. Clément-Lacroix, C. Robin-Jagerschmidt, D. Fleury, D. Guédin, P. Deprez, *J. Med. Chem.* **2012**, 55, 8225.
- [3] For examples of catalytic asymmetric  $\alpha$ -arylations, see: a) J. Åhman, J. P. Wolfe, M. V. Troutman, M. Palucki, S. L. Buchwald, *J. Am. Chem. Soc.* **1998**, 120, 1918; b) D. J. Spielvogel, S. L. Buchwald, *J. Am. Chem. Soc.* **2002**, 124, 3500; c) G. Chen, F. Y. Kwong, H. O. Chan, W.-Y. Yu, A. S. C. Chan, *Chem. Commun.* **2006**, 1413; d) X. Liao, Z. Weng, J. F. Hartwig, *J. Am. Chem. Soc.* **2008**, 130, 195; e) A. M. Taylor, R. A. Altman, S. L. Buchwald, *J. Am. Chem. Soc.* **2009**, 131, 9900; f) A. Bigot, A. E. Williamson, M. J. Gaunt, *J. Am. Chem. Soc.* **2011**, 133, 13778; g) J. S. Harvey, S. P. Simonovich, C. R. Jamison, D. W. C. MacMillan, *J. Am. Chem. Soc.* **2011**, 133, 13782; h) A. E. Allen, D. W. C. MacMillan, *J. Am. Chem. Soc.* **2011**, 133, 4260; i) J. Guo, S. Dong, Y. Zhang, Y. Kuang, X. Liu, L. Lin, X. Feng, *Angew. Chem. Int. Ed.* **2013**, 52, 10245; *Angew. Chem.* **2013**, 125, 10435.
- [4] F. Terrier, *Modern Nucleophilic Aromatic Substitution*, Wiley-VCH, Weinheim, **2013**.
- [5] For recent reviews on asymmetric phase-transfer catalysis, see: a) M. J. O'Donnell, *Aldrichimica Acta* **2001**, 34, 3; b) K. Maruoka, T. Ooi, *Chem. Rev.* **2003**, 103, 3013; c) M. J. O'Donnell, *Acc. Chem. Res.* **2004**, 37, 506; d) B. Lygo, B. I. Andrews, *Acc. Chem. Res.* **2004**, 37, 518; e) J. Vachon, J. Lacour, *Chimia* **2006**, 60, 266; f) T. Ooi, K. Maruoka, *Angew. Chem. Int. Ed.* **2007**, 46, 4222; *Angew. Chem.* **2007**, 119, 4300; g) T. Ooi, K. Maruoka, *Aldrichimica Acta* **2007**, 40, 77; h) T. Hashimoto, K. Maruoka, *Chem. Rev.* **2007**, 107, 5656; i) K. Maruoka, *Org. Process Res. Dev.* **2008**, 12, 679; j) S.-s. Jew, H.-g. Park, *Chem. Commun.* **2009**, 7090; k) K. Maruoka, *Chem. Rev.* **2010**, 10, 254; l) S. Shirakawa, K. Maruoka, *Angew. Chem. Int. Ed.* **2013**, 52, 4312; *Angew. Chem.* **2013**, 125, 4408.
- [6] a) M. Bella, S. Kobbelaard, K. A. Jørgensen, *J. Am. Chem. Soc.* **2005**, 127, 3670; b) S. Kobbelaard, M. Bella, K. A. Jørgensen, *J. Org. Chem.* **2006**, 71, 4980; c) S. Shirakawa, K. Yamamoto, T. Tokuda, K. Maruoka, *Asian J. Org. Chem.* **2014**, 3, 433; d) S. Shirakawa, K. Koga, T. Tokuda, K. Yamamoto, K. Maruoka, *Angew. Chem. Int. Ed.* **2014**, 53, 6220; *Angew. Chem.* **2014**, 126, 6334.
- [7] For reviews on arene chromium complexes in organic synthesis, see: a) K. Kamikawa, M. Uemura, *Synlett* **2000**, 938; b) A. Berger, J.-P. Djukic, C. Michon, *Coord. Chem. Rev.* **2002**, 225, 215; c) S. E. Gibson, H. Ibrahim, *Chem. Commun.* **2002**, 2465; d) A. Salzer, *Coord. Chem. Rev.* **2003**, 242, 59; e) M. Rosillo, G. Domínguez, J. Pérez-Castells, *Chem. Soc. Rev.* **2007**, 36, 1589.
- [8] a) M. Chaari, J.-P. Laverne, P. Viallefont, *Synth. Commun.* **1989**, 19, 1211; b) F. Rose-Munch, K. Aniss, E. Rose, *J. Organomet. Chem.* **1990**, 385, C1; c) M. Chaari, A. Jenhi, J.-P. Laverne, P. Viallefont, *Tetrahedron* **1991**, 47, 4619.
- [9] For reviews on asymmetric syntheses of  $\alpha,\alpha$ -disubstituted  $\alpha$ -amino acids, see: a) C. Cativiela, M. D. Díaz-de-Villegas, *Tetrahedron: Asymmetry* **1998**, 9, 3517; b) C. Cativiela, M. D. Díaz-de-Villegas, *Tetrahedron: Asymmetry* **2000**, 11, 645; c) Y. Ohfuné, T. Shinada, *Eur. J. Org. Chem.* **2005**, 5127; d) H. Vogt, S. Bräse, *Org. Biomol. Chem.* **2007**, 5, 406.
- [10] a) T. Ooi, M. Takeuchi, M. Kameda, K. Maruoka, *J. Am. Chem. Soc.* **2000**, 122, 5228; b) T. Ooi, M. Kameda, K. Maruoka, *J. Am. Chem. Soc.* **2003**, 125, 5139.
- [11] a) M. Kitamura, S. Shirakawa, K. Maruoka, *Angew. Chem. Int. Ed.* **2005**, 44, 1549; *Angew. Chem.* **2005**, 117, 1573; b) M. Kitamura, S. Shirakawa, Y. Arimura, X. Wang, K. Maruoka, *Chem. Asian J.* **2008**, 3, 1702.
- [12] S. Shirakawa, K. Yamamoto, K. Liu, K. Maruoka, *Org. Synth.* **2013**, 90, 121.
- [13] a) Z. Han, Y. Yamaguchi, M. Kitamura, K. Maruoka, *Tetrahedron Lett.* **2005**, 46, 8555; b) Y.-G. Wang, M. Ueda, X. Wang, Z. Han, K. Maruoka, *Tetrahedron* **2007**, 63, 6042.
- [14] For the preparation of saturated aqueous CsOH (80 wt % aq. CsOH), see Ref. [12].
- [15] The reaction on larger scale (10 times) gave a similar result (74 % yield, 97 % ee).
- [16] For details of the determination of the absolute configuration of **3a**, see the Supporting Information.
- [17] Racemic arene chromium complexes **2c**, **2d**, and **2f** were used for the reaction.